Intrahepatic bile acid accumulation due to inhibition of the bile salt export pump (BSEP) has been proposed as a mechanism for drug-induced cholestasis. Many cholestatic drugs do not initiate hepatotoxicity in rats, although they inhibit rat Bsep and cause elevated serum bile acid concentration. In this study, we examined changes in the taurocholate (TC) transport in response to cholestatic drug treatments in human and rat sandwich-cultured hepatocytes. Our experimental setup allows studying the basolateral and canalicular efflux simultaneously, thus comparing drug-induced changes in the vectorial efflux of TC. We found that TC elimination highly differs in human and rat hepatocytes. In human hepatocytes, an equal fraction of TC uptake was eliminated by basolateral (34.8%) and canalicular (34.4%) transporters and remained in the cells (30.5%), while in the case of rats, the basolateral transport was dominant (71.7%) and intracellular TC accumulation was negligible (6.9%). The inhibition of BSEP/Bsep resulted in significantly higher intracellular TC conc in humans than in rats. The 15-fold difference in intracellular TC conc of control in human versus rat hepatocytes was increased 25-fold by troglitazone treatment. MK571 and indomethacin decreased the basolateral efflux and significantly increased the intracellular TC conc in rats. In rat hepatocytes, the highest intracellular TC conc was observed with cyclosporine A and glibenclamide, which inhibited TC elimination in both directions. Nevertheless, the basolateral transport remained dominant. We conclude that in rats, the higher rate of basolateral bile salt efflux represents an additional protective mechanism in cholestasis, which contributes to species differences in response to hepatotoxic drugs.
Drug-induced cholestasis is a pressing issue for both patient safety and for the pharmaceutical industry. Only 50% of clinical incidences of hepatotoxicity are predicted with standard rodent preclinical tests (Olson et al., 2000) , which is partly due to the fact that many drugs causing cholestasis in humans do not induce hepatotoxicity in rats (Fattinger et al., 2001 ). The production of bile is dependent upon the coordinated regulation and function of several basolateral and canalicular transport proteins, such as Na þ -dependent TC cotransport protein (NTCP), bile salt export pump (BSEP), multidrug resistance associated protein 2/3/4 (Mrp2/3/4), etc. Zollner et al., 2001) . Experimental animal studies have shown that reduced expression of hepatobiliary transport systems may explain impaired bile excretory function resulting in cholestasis (Akita et al., 2002b; Ohashi et al., 2002; Trauner et al., 1999) . BSEP has been found to be a target for drug-induced liver injury (Fattinger et al., 2001; Stieger et al., 2000) , and inhibition of this canalicular transporter may be an important mechanism in acquired forms of cholestasis. Bile acid accumulation in hepatocytes due to the inhibition of BSEP has been proposed as a mechanism for hepatotoxicity induced by several drugs, such as cyclosporin A, rifampicin, bosentan, troglitazone, glibenclamide, etc. (Akashi et al., 2006; Crocenzi et al., 2003; Funk et al., 2001) .
Several drugs that cause cholestasis in humans do not induce hepatotoxicity in rats, although many of them have been reported to inhibit rat Bsep and cause elevated serum bile acid concentration (Fattinger et al., 2001; Funk et al., 2001; Hung et al., 2005) . The lack of hepatotoxicity induced by these drugs in rats is explained by the inhibition of uptake of bile salts into hepatocytes and/or the difference in susceptibility for BSEP/Bsep inhibition (Horikawa et al., 2003) . In a recent study, bosentan was found to be a more potent inhibitor for Ntcp than NTCP, and this resulted in less intrahepatocyte accumulation of bile acids in rats during bosentan treatment . However, the mechanism of drug-induced cholestasis and the molecular bases of interspecies differences in response to cholestatic drug treatment are not fully understood. Presently, there are no means for accurate prediction of risk of cholestasis in humans.
Many in vitro techniques have been used to identify transporters involved in drug-induced cholestasis; however, there are pitfalls in extrapolating in vitro findings to in vivo situations, not to say extrapolation from rats to humans (Kostrubsky et al., 2006; Marion et al., 2007; Mita et al., 2006) . Due to ethical and financial limitations of in vivo studies, experiments using primary hepatocytes provide the nearest approach to in vivo for getting an insight into molecular bases of drug-induced cholestasis and also to compare cholestatic potential of drugs in different species. Sandwichcultured hepatocytes (SCHs) preserve metabolizing and transport capacities better than hepatocytes maintained in rigid configuration (RCH). In SCH, membrane components are localized to their respective basolateral and canalicular domains. Within a few days, a functional biliary network is formed between adjacent cells, hepatocytes regain vectorial transport ability, and thus, this in vitro model is suitable to study the expression and function of basolateral and canalicular transporters even in human cells (LeCluyse et al., 2000) .
We, therefore, used SCH originated from human and rat liver to study whether cholestatic drugs affect the vectorial efflux of taurocholate (TC), which was proposed as one of the mechanisms leading to hepatotoxicity (Crocenzi et al., 2003; Fattinger et al., 2001) . In this in vitro model, we could compare the effect of cholestatic drugs on the function of basolateral and canalicular efflux transporters in human and rat hepatocytes directly. We measured the uptake and the basolateral and canalicular efflux of TC and showed that basolateral efflux represents a more important pathway for TC elimination in rat than in human hepatocytes. This is the first time that basolateral transport has been distinguished from canalicular transport in both human and rat hepatocytes. The intracellular accumulation of TC was significantly higher in human cells compared to that in rats, and this difference was largely caused by the inhibition of the canalicular transport. In rats, the intracellular TC levels were more sensitive to the inhibition of basolateral than that of canalicular transport. Based on these results, we concluded that apart from species differences in susceptibility to inhibition of NTCP/Ntcp and BSEP/Bsep, which has been reported previously (Horikawa et al., 2003; Leslie et al., 2007) , the pronounced contribution of basolateral transport to bile salt elimination might provide a further compensatory pathway to avoid hepatotoxicity during cholestatic drug treatment in rats.
MATERIALS AND METHODS

Chemicals. [
3 H]Taurocholic acid (10 Ci/mmol) was obtained from American Radiolabeled Chemicals Inc. (St Louis, MO); collagenase, taurocholic acid, cyclosporine A, indomethacin, glucagon, glybenclamide, ketoconazole, troglitazone, dexamethasone, and William's Medium E were purchased from Sigma-Aldrich Ltd (Budapest, Hungary); and MK571 was obtained from Calbiochem (Darmstadt, Germany). Matrigel was purchased from BD Biosciences (Bradford, MD). All other chemicals were analytical grade and readily available from commercial sources.
Preparation and culture of primary human and rat hepatocytes. Human liver tissues were obtained from kidney transplant donors by a qualified medical staff from Transplantation and Surgical Clinic, Semmelweis University of Budapest, as rejected donor livers. Permission of the Hungarian Regional Committee of Science and Research Ethics was obtained to use human tissues for scientific purposes. All studies involving human tissue followed the principles of the Declaration of Helsinki. Rat hepatocytes were prepared from male Wistar rats (250-350 g; Charles River, Budapest, Hungary). Animals had free access to water and food prior to surgery. Hepatocytes were prepared by a three-step perfusion procedure (Bayliss and Skett, 1996) . Cell viability (> 90%) was determined by trypan blue exclusion. All procedures were approved by the Institutional Animal Care and Use Committee. Hepatocytes were plated at a density of 2.0 3 10 6 cells/well on 6-well plates for SCH, and 0.35 3 10 6 cells/well on 24-well plates for RCH, in William's Medium E containing 5% of fetal calf serum, 0.1lM insulin, 0.05lM glucagon, 0.1 mg/ml gentamicin, 30nM Na 2 SeO 3 , and 0.1lM dexamethasone. Calf serum was present for the first 24 h and then omitted. Cells were maintained at 37°C in a humidified atmosphere of 95% air-5% CO 2 . Twenty-four hours after plating, cells were overlaid with matrigel basement membrane matrix at a concentration of 0.25 mg/ml in 2 ml of ice-cold William's Medium E supplemented with insulin, glucagon, gentamicin, dexamethasone, and Na 2 SeO 3 to achieve sandwich configuration. The only difference between RCH and SCH was that the former was not overlayed. Human and rat hepatocytes were cultured for further 6 and 3 days, respectively; medium was changed daily. For betanaphtoflavone (BNF) induction, rat hepatocytes were treated with 50lM BNF on first and second days of culturing. Uptake and efflux experiments were carried out on the seventh (human) and the fourth day (rat) of culturing.
Uptake study in SCH. Human and rat SCH were rinsed with standard Hanks' balanced salt solution (HBSS) buffer and incubated with 1lM 3 H TC in standard HBSS for 1 min at 37°C. Uptake was terminated by removal of the substrate-containing buffer, and wells were rinsed three times with ice-cold standard HBSS. Cells were lysed with 1 ml of 0.5% Triton X-100 in HBSS by shaking for 20 min at room temperature. An aliquot of lysate was analyzed by liquid scintillation spectrometry.
Efflux studies in SCH. The efflux studies were carried out as described previously (Lengyel et al., 2008) . Briefly, hepatocytes were incubated with 1 ml of 1lM 3 H TC for 1 min at 37°C. Then, the substrate-containing medium was removed, and the cells were rinsed three times with 1.0 ml of ice-cold standard or Ca -and Mg 2þ -free HBSS supplemented with the modulator compounds or the vehicle for 10 min at 37°C or at 4°C in a humidified atmosphere of 95% air-5% CO 2 , respectively. Efflux was terminated by removal of the modulator-containing buffer, and wells were rinsed with icecold standard HBSS. Cells were lysed with 1 ml of 0.5% Triton X-100 in HBSS by shaking for 20 min at room temperature. The amount of TC in the efflux medium and the lysates were analyzed by liquid scintillation spectrometry. The nonspecific TC binding was taken into consideration by subtracting radioactivity measured in the efflux medium and lysates of wells without hepatocytes from that obtained in the presence of hepatocytes. Protein content of lysates was determined by the method of Lowry et al. (1951) .
Efflux study in rigid culture of hepatocyte (RCH). The efflux studies in RCH were carried out similarly to that in SCH except that the experiments were carried out in standard HBSS. Since no canalicular networks are formed in rigid configuration resulting in combined expression of sinusoidal and canalicular transporters on the membrane surface, there is no reason to use Ca 2þ -and Mg 2þ -free HBSS. The time for TC uptake was prolonged to 15 min. After this, the substrate-containing medium was removed, and the cells were rinsed three times with ice-cold HBSS. Then, the cells were incubated with HBSS supplemented with the modulator compounds or the vehicle for 15 min at 37°C in a humidified atmosphere of 95% air-5% CO 2 . Efflux was terminated by removal of the modulator-containing buffer, and wells were rinsed with icecold HBSS. Cells were lysed with 1 ml of 0.5% Triton X-100 in HBSS by shaking for 20 min at room temperature. The amount of TC in the lysates was analyzed by liquid scintillation spectrometry.
BASOLATERAL TC EFFLUX CAN PREVENT TOXICITY
Data analysis. Uptake of TC (TC uptake ) was determined from the lysates of cells following 1-min incubation in standard HBSS containing 1lM TC at 37°C. Data are expressed as mean ± SD (n ¼ 3-5).
In standard HBSS, the bile canaliculi remain intact; therefore, sinusoidal transport was calculated by the amount of TC observed in standard efflux medium following a 10-min incubation at 37°C. The contribution of other processes to the efflux of TC such as passive transport and leakage into standard medium was evaluated from the rate of TC transport into standard medium following a 10-min incubation at 4°C. The active basolateral transport was calculated by subtracting the amount of TC in standard efflux medium at 4°C from that at 37°C.
In the absence of Ca 2þ and Mg 2þ , the bile canaliculi tight junctions are disrupted; therefore, the transport of TC into the canalicular networks was determined by subtracting the amount of TC in lysate of cells incubated in Ca 
RESULTS
Uptake, Basolateral, Canalicular Efflux, and Intracellular Accumulation of TC in Human and Rat SCH
The balance of uptake and efflux processes, taking place simultaneously, determines the amount of TC accumulated in hepatocytes. In preliminary studies, we found that the uptake of TC was very rapid, the intracellular TC concentration became constant in 2-3 min of incubation, and that was the reason why we chose 1 min for uptake. Following 1 min of incubation in standard HBSS containing 1lM TC at 37°C and 4°C, respectively, the uptake of TC was defined as the amount of TC measured in the lysate of cells. Figure 1 shows that twice as much TC got into human than into rat hepatocytes within 1 min at 37°C (TC uptake ) (42.3 ± 9.6 and 23.4 ± 4.6 pmol/mg protein respectively). No TC uptake was observed at 4°C (data not shown). In efflux experiments, following the uptake period, the substrate was washed out and hepatocytes were incubated in standard or Ca 2þ -and Mg 2þ -free HBSS for 10 min. The basolateral and canalicular efflux of TC was determined as it was described in ''Materials and Methods'' section. Significant difference was found in the efflux pattern of human and rat hepatocytes (Fig. 1) . Equal amount of TC was transported by basolateral and canalicular efflux processes (34.8± 13.9 and 34.4 ± 12.4% of TC uptake , respectively) in human SCH, while in rats, the basolateral transport was threefold higher than the biliary transport (71.7 ± 16.2 and 23.3 ± 7.6% of TC uptake , respectively). Intracellular accumulation of TC was much higher in human hepatocytes than that in rats (30.5 ± 14.5 and 6.9 ± 4.1% of TC uptake , respectively), showing that 15-fold higher amount of TC remained in human than in rat hepatocytes. In order to estimate the share of active transport in the overall TC free HBSS at 37°C or at 4°C, respectively. Uptake was determined from the lisates of cells following 1 min of incubation with 1lM 3 H TC at 37°C. For BNF induction, rat hepatocytes were treated with 50lM BNF on the first and second days of culturing. Efflux and accumulation of TC was determined as described in ''Materials and Methods'' section. Values are expressed as mean ± SD of at least five separate experiments in triplicate. 82 elimination, following a 1-min uptake period at 37°C, the efflux part of the experiments was performed at 4°C. Figure 1 shows that 26.2 ± 3.4 and 2.2 ± 1.3% of TC uptake was eliminated into the basolateral and canalicular space during 10 min of efflux, and 71.0 ± 5.9% of TC uptake remained inside the cells at 4°C. The difference in TC transport measured at 37°C and 4°C was considered as active transport. BNF treatment of rat hepatocytes resulted in a twofold increase in TC uptake, with no significant change of intracellular accumulation (Fig. 1) .
Intracellular Accumulation of TC in the Presence of
Troglitazone in Human and Rat SCH Following a 1-min uptake period in the presence of TC, the substrate was washed out and human and rat SCH were incubated in standard or Ca 2þ -and Mg
2þ
-free HBSS supplemented with 1, 10, and 100lM troglitazone or the vehicle (0.1% dimethyl sufoxide [DMSO]) for 10 min. The amount of TC accumulated in the cells was determined from the lysates of hepatocytes incubated in Ca 2þ -and Mg 2þ -free HBSS, in which the canalicular networks opened during 10 min. Figure 2 shows that in the presence of troglitazone, the intracellular TC level increased concentration dependently in both human and rat SCHs. In the presence of 100lM troglitazone, TC accumulation increased twofold and threefold in rat and human hepatocytes, respectively, wherefore the difference in intracellular TC accumulation in human and rat hepatocytes increased from 15-to 25-fold.
Modulation of TC Efflux and Accumulation by Drugs in
Human and Rat SCH Previous studies confirmed that BSEP (Meier and Stieger, 2002) and multidrug resistance associated protein (MRP)3/4 (Hirohashi et al., 2000; Rius et al., 2006) are the major transporters involved in TC transport across the canalicular and basolateral surface, respectively. Several drugs, known inhibitors for BSEP and MRPs, were chosen to assess the contribution to TC elimination of canalicular and basolateral transporters, which determine the intracellular accumulation of TC in human and rat hepatocytes. Following a 1-min uptake period in the presence of TC, the substrate was washed out and SCHs were incubated in standard or Ca 2þ -and Mg 2þ -free HBSS supplemented with 100lM troglitazone, ketoconazole, glibenclamide, indomethacin, MK571, and 50lM cyclosporine A, respectively, or the vehicle (0.1% DMSO) for 10 min at 37°C. Basolateral transport was determined from the efflux media of cells incubated in standard HBSS, and transport data of experiments performed at 4°C were taken into correction. No difference was obtained comparing efflux and accumulation data in the presence or absence of modulators at 4°C (data not presented). Canalicular transport and intracellular accumulation of TC were calculated as that was described in ''Materials and Methods'' section. As it was expected, in human SCH, glibenclamide, ketoconazole, and troglitazone significantly decreased the canalicular transport of TC (44.0 ± 23.7, 36.9 ± 5.5, and 14.4 ± 14.0% of the control, respectively), while the basolateral transport was not altered (Table 1) . TC accumulation was extremely high in the presence of troglitazone (293.2 ± 31.3% of the control), which was the most effective BSEP inhibitor in human cells. Glibenclamide and ketoconazole decreased BSEP activity to a lesser degree, associated with smaller intracellular TC levels (182.4 ± 37.7 and 137.4 ± 4.4, respectively). In case of rat hepatocytes, the elevated intracellular TC concentration seems to be the joint effect of decreased basolateral and canalicular transport processes. As shown in Table 1 , the most striking increase in TC accumulation was revealed in the presence of cyclosporine A (348.3 ± 21.5), which was the result of the highly decreased TC efflux to both directions (8.3 ± 4.1 and 45.3 ± 9.6% of control, respectively). Similarly, glibenclamide decreased the efflux of TC to both directions, but here, the basolateral efflux was affected more significantly (65.5 ± 8.5 and 28.5 ± 7.1% of control, respectively) leading to a 2.5-fold increase in the intracellular TC concentration. MK571 and indomethacin, well-known MRP/Mrp inhibitors, did not affect the canalicular efflux, but both compounds considerably decreased the basolateral transport of TC (42.4 ± 9.4 and 63.2 ± 13.3% of the control, respectively). Thus, TC accumulation significantly increased (326.3 ± 40.4 and 221.0 ± 41.8% of the control, respectively). The intracellular TC accumulation was smaller in the presence of troglitazone (194.1 ± 21.5% of control) than that of MK571, although the canalicular transport was decreased by more than 60% by troglitazone. From BASOLATERAL TC EFFLUX CAN PREVENT TOXICITY a toxicological point of view, the increase of intracellular bile salt concentration is of primary importance. In this regard, the inhibition of basolateral and/or canalicular TC transport modulated the intracellular TC levels in a totally different manner in human than in rat hepatocytes. In Figure 3 , we presented changes in TC efflux and accumulation patterns as a function of drug treatment. In human hepatocytes, the inhibition of BSEP led to high intracellular TC levels, while the basolateral transport did not change. The lowest canalicular TC transport in case of troglitazone treatment was accompanied with the highest intracellular TC concentration (3.8 ± 3.7 and 71.4 ± 7.6% of TC uptake , respectively). In contrast, in rats, the impaired basolateral TC transport seems to exert more influence on intracellular TC accumulation than the inhibition of Bsep, which is not surprising since only 23.3% of TC uptake was transported into the canalicular networks in control hepatocytes (Fig. 1) . Although the inhibition of canalicular TC transport in rat hepatocytes by troglitazone and ketoconazole resulted in an increase of intracellular TC levels just like in humans, the basolateral transport remained the decisive pathway of TC elimination (75.6 ± 10.3 and 81.3 ± 9.1% of TC uptake , respectively). The highest intracellular TC levels were observed in the presence of cyclosporine A and glibenclamide, which decreased TC elimination in both directions, but even in these cases, the basolateral transport played a significant role in the overall transport process (55.7 ± 9.2 and 40.2 ± 12.7% of TC uptake , respectively). The proportion of intracellular TC was higher in cells treated with MK571 and indomethacin (28.3 ± 7.9 and 17.3 ± 7.4% of TC uptake , respectively), which inhibited the basolateral transport only, than in troglitazoneand ketoconazole-treated cells (15.6 ± 2.2 and 7.6 ± 1.6% of TC uptake , respectively), showing that decreased basolateral transport has a major effect on TC accumulation in rats (Fig. 3) .
Modulation of TC Accumulation in Rat RCH
Next, we compared the effect of the same set of drugs on TC accumulation in rat RCH. In RCH, basolateral and canalicular transporters are expressed mixed on the cell surface; therefore, no distinction between the directions of TC elimination can be made. In preliminary studies, we found that the uptake of TC in RCH is significantly slower than in SCH (data not shown); therefore, we extended the time of both the uptake and the efflux periods to 15 min. Following uptake, the substrate was washed out and cells were incubated in standard HBSS supplemented with 10, 50, and 100lM troglitazone, ketoconazole, glibenclamide, indomethacin, and 1, 10, and 50lM cyclosporine A, respectively, or the vehicle (0.1% DMSO) at 37°C. TC accumulation was determined as described in ''Materials and Methods'' section. As shown in Figure 4 , all compounds used increased the intracellular TC accumulation in a concentration-dependent manner. Although cyclosporine A and glibenclamide treatment produced the highest intracellular TC levels (136.9 and 195.5% of the control at 10 and 50lM cyclosporine A and 143.4 and 178.9% of the control at 50 and 100lM glibenclamide), there was not so significant difference between the effects of drugs. Indomethacin, troglitazone, and ketoconazole treatment resulted in much lower TC accumulation in RCH than in SCH (155.1, 137.8, and 158.7% of the control at 100lM concentration, respectively).
DISCUSSION
Inhibition of BSEP by cholestatic drugs has been suggested as one of the mechanisms initiating liver injury in humans, probably due to high intracellular bile salt concentration Stieger et al., 2000) . Many cholestatic drugs inhibiting rat Bsep do not induce hepatotoxicity in rats. This study provides direct evidence that the elimination pattern of TC highly differs in human and rat hepatocytes. Our results clearly show that contribution of canalicular and basolateral transport is equal to TC elimination in human SCH, while basolateral efflux corresponds to 75% of TC elimination in rats (Fig. 1) . From a toxicological point of view, an even more 84 important difference was that after 10 min of efflux, only 6.9% of TC uptake remained in rat hepatocytes compared to 30.5% of that in humans. It follows that the same fold increase of TC accumulation by drug interactions results in significantly higher intracellular bile salt concentration accompanied with higher risk of hepatotoxicity in humans than in rats. Human hepatocytes expressed twofold TC uptake activity compared to rat cells, which is consistent with kinetic parameters of TC FIG. 3 . Changes in TC efflux and accumulation pattern in response to cholestatic drug and Mrp3/4 inhibitor treatments in human and rat SCH. Human (A) and rat (B) hepatocytes were incubated for 1 min with 1lM 3 H TC in standard HBSS at 37°C, then the substrate was washed out, and the hepatocytes were incubated for further 10 min in standard or Ca 2þ -and Mg 2þ -free HBSS containing 100lM glibenclamide, troglitazone, ketoconazol, indomethacin, MK571, and 50lM cyclosporine A, respectively, or the vehicle (0.1% DMSO) at 37°C. Efflux and accumulation of TC was determined as described in ''Materials and Methods'' section. Values are expressed as % of TC uptake , mean ± SD of at least three separate experiments in triplicate.
BASOLATERAL TC EFFLUX CAN PREVENT TOXICITY transport by NTCP and Ntcp published by Leslie et al. (2007) . They described 2.3-fold higher V max for human protein than for rat protein. BNF treatment of rat hepatocytes resulted in twofold TC uptake compared to the control, leading to similar uptake activity as observed in human hepatocytes. As a result of the elevated TC uptake, the 10.5:2.8:1 basolateral efflux:canalicular efflux:intracellular accumulation ratio changed to 6:2.1:1 compared to 1:1:1 of humans. The still low intracellular accumulation in BNF-treated rat cells supports that species difference in TC uptake is not responsible for the elevated intracellular TC accumulation of human hepatocytes. Troglitazone, glibenclamide, and cyclosporine A were found to interfere with the hepatobiliary elimination of bile salts by inhibition of Bsep in rats (Akashi et al., 2006; Funk et al., 2001; Marion et al., 2007) and also in humans, contributing to the initiation of drug-induced liver toxicity (Horikawa et al., 2003; Mita et al., 2006) . Here, we show that all of these drugs caused potent inhibition of BSEP/Bsep both in human and in rat hepatocytes, resulting in significant increase in TC accumulation. The 15-fold difference between human and rat intracellular TC accumulation measured in control SCH increased to 25-fold by troglitazone treatment. Accordingly, negligible amount of intracellular TC was observed in rat hepatocytes even in the presence of troglitazone compared to humans (Fig. 2) . Similar results were obtained with glibenclamide and ketoconazole in human SCH. In rat hepatocytes, glibenclamide and cylsosporine A inhibited the efflux of TC in both directions, resulting in much pronounced increase of TC accumulation than that was observed in the presence of troglitazone and ketoconazole, which interfered with the canalicular transport only (Fig. 3) .
MRP3/4 and Mrp3/4 have been suggested as major bile acid efflux pumps on the basolateral surface of hepatocytes (Akita et al., 2002b; Rius et al., 2006; Zeng et al., 2000) . Experiments with membrane vesicles prepared from Sf9 cells expressing human and rat MRP3/Mrp3 provided direct evidence that TC was transported significantly by Mrp3 but not by MRP3 (Akita et al., 2002a) . This is in good agreement with our findings that basolateral transport of TC is much more important in rat than in human hepatocytes (Fig. 1) . Low MRP3/Mrp3 expression (Donner and Keppler, 2001) highly increases in cholestasis together with Mrp4 and serves as an overflow for toxic endogenous compounds such as bile salts to prevent liver injury (Denk et al., 2004; Donner and Keppler, 2001) . Belinsky et al. (2005) provided direct evidence that Mrp3 protects cholestatic hepatocytes from bile acids by showing that Mrp À / À mice subjected to bile duct ligation have higher intrahepatic bile acid level compared to wild type. Our results propose that this major difference in bile salt transport capacity of MRP3 and Mrp3, which highly contribute to defense against liver injury in cholestasis, might be a reason for species differences in susceptibility to cholestatic drugs. To support   FIG. 4 . Effect of cholestatic drug and Mrp3/4 inhibitor treatments on intracellular TC accumulation in rat RCH. Hepatocytes were incubated for 15 min with 1lM 3 H TC in standard HBSS at 37°C, then the substrate was washed out, and the hepatocytes were incubated for further 15 min in standard HBSS containing 10, 50, and 100lM troglitazone, glibenclamide, ketoconazole, indomethacin, and 1, 10, and 50lM cyclosporine A, respectively, or the vehicle (0.1% DMSO) at 37°C. Accumulation of TC was determined as described in ''Materials and Methods'' section. Values are expressed as mean ± SD of at least three separate experiments in triplicate. 86 that the high rate of basolateral bile acid transport in rats has a major part in the protection against high intracellular accumulation of these toxic compounds, we studied the effect of MK571 and indomethacin, known Mrp3/4 inhibitors (Bodó et al., 2003; Rius et al., 2003) . Our results demonstrate that these drugs did not interfere with Bsep. Both compounds significantly decreased the share of basolateral transport in TC elimination, which led to elevated intracellular TC level (Fig. 3) . In rat SCH, the highest intracellular TC levels were obtained by simultaneous inhibition of basolateral and canalicular TC transport as it was observed with cyclosporine A and glibenclamide. Intracellular TC accumulation was more sensitive to the decrease of the basolateral transport than to the inhibition of Bsep. Cholestasis is not the only occasion when upregulation of basolateral Mrp3/4 may serve to limit the chemical burden of hepatocytes. Similar compensatory changes were reported during critical stages of regeneration and repair following induction of acute liver injury. Acetaminophen (APAP)-induced hepatotoxicity results in overexpression of Mrp3 and Mrp4 messenger RNA (mRNA) and protein.
Treatment of mice with APAP led to induction of Mrp3 and Mrp4 proteins that correlated with a significant reduction in hepatotoxicity following challenge with a higher dose of APAP (Aleksunes et al., 2008) . Human liver specimens from APAP cases also exhibited increased levels of MRP4 mRNA and protein (Barnes et al., 2007) .
Human and rat SCH are commonly used to estimate the biliary efflux of compounds and also to assess hepatotoxic potential of drugs due to interaction with biliary efflux processes (Kemp and Brouwer 2004; Liu et al., 1999) . In a recent paper, the mechanism of cholestatic drug-induced hepatotoxicity has been reviewed according to studies carried out in SCH (Marion et al., 2007) . They presented that troglitazone and bosentan inhibit both the uptake and the biliary excretion of bile acids. The balance between inhibition of uptake and efflux of bile acids could be very important and might be a reason for interspecies differences. In the experimental design of these studies, the uptake and efflux of TC were not separated and were taking place in the presence of the modulator drugs; consequently, changes in intracellular TC concentration showed the overall effect of drugs on both uptake and efflux processes. Our experimental setup, which uncouples the uptake and efflux pathways, gives rise to study the vectorial (basolateral and canalicular) transport of a compound and also to assess the effect of drugs interfering with any of these processes. Reuptake following washing out the substrate should be negligible during the efflux period since not more than 4.5 and 2.3% of TC got into the human and rat hepatocytes, respectively, during the uptake period. TC concentration during the uptake period was 1lM. Total uptake was less than 5% of which less than 50% appeared in the efflux medium (Fig. 1) . Based on these data, the maximal TC concentration in the efflux medium should be less than 25nM, which is orders of magnitudes lower than the Km values for TC reported (25 and 6lM for Ntcp and NTCP, respectively, Leslie et al., 2007) . Our method allowed us to observe a further compensatory route, other than the decrease of TC uptake in response to Bsep inhibition, and it revealed that the basolateral efflux contributes to interspecies differences in hepatotoxic outcome following cholestatic drug treatment. Until now, the role of basolateral transport in cholestasis could be determined by in vivo or liver perfusion experiments only. Our study is the first in which the consequences of drug interactions with basolateral and canalicular transport were assessed in vitro in SCH.
We studied the effect of the same setup of drugs on TC accumulation in RCH as well in order to show the advantage of SCH compared to RCH. All drugs studied enhanced the intracellular TC level irrespective of whether they inhibited the activity of Bsep, Mrp3/4, or both. Although in RCH cyclosporine A elevated the cellular TC level most potently like in SCH, only minor difference was observed between the effect of drugs; thus, the outcome observed in case of inhibition of canalicular or basolateral TC transport did not differ (Fig. 4) . Using rat RCH to assess cholestatic potential of drugs, no conclusion can be drawn concerning which transporters are responsible for the increase of intracellular TC accumulation, albeit the risk of cholestasis for humans highly depends on whether the drugs interfere with canalicular or basolateral transport of bile salts.
In conclusion, our results have shown that the hepatic disposition of TC highly differs in human and rat SCH. In rats, the basolateral transport is the dominant pathway of TC efflux, and negligible amount of TC remains inside the cells following 10 min of efflux. In contrast, the basolateral and canalicular transport shares equal part in TC efflux, and considerable amount of TC was accumulated in the cells of human SCH. In rats, the high rate of basolateral transport prevented the significant intracellular TC accumulation in case of Bsep inhibition, while human hepatocytes were much more sensitive to BSEP inhibition leading to significantly higher cellular TC levels. Our results suggest that dissimilar contribution of basolateral transport to TC efflux in humans and rats might represent an additional mechanism, which is responsible for species differences in response to hepatotoxic drugs. The finding that human MRP3 does not transport TC in contrast to rat Mrp3 might be one of the reasons for this. However, insufficient information is available concerning MRP4/Mrp4 expression in healthy and cholestatic humans and rats.
